Praxis Precision Medicines, INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
NASDAQ
Praxis Precision Medicines CEO Marcio Souza reports a gift of common stock to a trust, impacting his beneficial ownership.
NASDAQ
Jill DeSimone, a Director at Praxis Precision Medicines, Inc., reported transactions involving the sale of common stock and the acquisition of stock options on June 24, 2026.
NASDAQ
Director Stuart Arbuckle acquired 1,371 restricted stock units and 648 stock options in Praxis Precision Medicines, Inc.
NASDAQ
Director Jeffrey Chodakewitz was granted 1,371 restricted stock units and 648 stock options by Praxis Precision Medicines.
NASDAQ
Director William D. Young was granted 1,371 restricted stock units and 648 stock options by Praxis Precision Medicines.
NASDAQ
Director Jill DeSimone acquired 1,371 restricted stock units and 648 stock options in Praxis Precision Medicines, Inc.
NASDAQ
Director Merit Cudkowicz received an equity grant of restricted stock units and stock options from Praxis Precision Medicines.
NASDAQ
Director Dean J. Mitchell acquired 1,371 restricted stock units and 648 stock options in Praxis Precision Medicines, Inc.
NASDAQ
Director Jeffrey Kindler acquired 1,371 restricted stock units and 648 stock options in Praxis Precision Medicines, Inc.
NASDAQ
Director Gregory Norden was granted 1,371 restricted stock units and 648 stock options by Praxis Precision Medicines, Inc.
NASDAQ
Lauren Mastrocola, Principal Accounting Officer of Praxis Precision Medicines, acquired 127 shares through the company's employee stock purchase plan.
NASDAQ
Alex Nemiroff, General Counsel of Praxis Precision Medicines, acquired 78 shares through the company's employee stock purchase plan.
NASDAQ
Timothy Edwin Kelly, Chief Financial Officer of Praxis Precision Medicines, acquired 121 shares of common stock through the company's Employee Stock Purchase Plan.
NASDAQ
Praxis Precision Medicines Chief Operating Officer Megan Sniecinski acquired 89 shares of common stock through the company's employee stock purchase plan.
NASDAQ
Praxis Precision Medicines CEO Marcio Souza acquired 126 shares of common stock through the company's Employee Stock Purchase Plan.
NASDAQ
Praxis Precision Medicines Director Stuart A. Arbuckle acquired 1,166 restricted stock units and 224 stock options.
NASDAQ
Praxis Precision Medicines Director Jeffrey B. Kindler was granted restricted stock units and stock options, aligning his interests with shareholders.
NASDAQ
Praxis Precision Medicines' Principal Accounting Officer, Lauren Mastrocola, reported a routine disposition of 344 common shares for tax withholding purposes.
NASDAQ
Praxis Precision Medicines' Chief Operating Officer, Megan Sniecinski, reported the withholding of 885 common shares for tax obligations related to restricted stock unit vesting.
NASDAQ
Praxis Precision Medicines' General Counsel, Alex Nemiroff, disposed of 768 common shares at $275.74 each to cover tax withholding obligations related to restricted stock unit vesting.
NASDAQ
Praxis Precision Medicines' CFO, Timothy Edwin Kelly, reported the disposition of 943 common shares to cover tax liabilities from vested restricted stock units.
NASDAQ
Praxis Precision Medicines' Principal Accounting Officer, Lauren Mastrocola, was awarded new restricted stock units and stock options, while also selling shares to cover tax obligations.
NASDAQ
Praxis Precision Medicines' COO, Megan Sniecinski, received new equity awards and sold shares to cover tax obligations.
NASDAQ
Praxis Precision Medicines' General Counsel, Alex Nemiroff, reported the acquisition of restricted stock units and stock options, alongside a disposition of shares for tax obligations.
NASDAQ
Praxis Precision Medicines CFO Timothy Kelly reports new restricted stock unit and stock option grants, alongside shares withheld for tax obligations.
NASDAQ
Praxis Precision Medicines CEO Marcio Souza was granted 27,640 restricted stock units and options for 22,110 shares, while also disposing of 4,252 shares for tax obligations.
NASDAQ
Praxis Precision Medicines' Principal Accounting Officer, Lauren Mastrocola, disposed of 35 common shares to cover tax obligations from vested restricted stock units.
NASDAQ
Praxis Precision Medicines' General Counsel, Alex Nemiroff, disposed of 89 shares of common stock to cover tax withholding obligations related to RSU vesting.
NASDAQ
Praxis Precision Medicines' CFO, Timothy Kelly, reported a routine disposition of 139 common shares to cover tax obligations from vested restricted stock units.
NASDAQ
Praxis Precision Medicines CEO Marcio Souza reported a disposition of 405 common shares to cover tax obligations related to restricted stock unit vesting.